Medical Weight Loss Services
US$ 27.65
glp-1 agonists cardiovascular diseases Glucagon-like peptide 1 receptor agonists: benefits and mechanisms of action The Unstoppable Rise of GLP-1
Description
no GLP-1 RA is on this list
doi:10.1126/science.287.5453.664 67
First, we emulated two cardiovascular outcome trials, SUSTAIN-6 (semaglutide versus sitagliptin as placebo proxy) and SURPASS-CVOT (tirzepatide versus dulaglutide), to benchmark and critically evaluate our design, data and analytic framework
Eur J Endocrinol (2019) 181(2):16171
doi: 10.1016/j.bja.2023.05.005
Report Scope Research Methodology of Verified Market Research: To know more about the Research Methodology and other aspects of the research study, kindly get in touch with our Sales Team at Verified Market Research
